Segment Information (Tables)

6 Months Ended

Jun. 30, 2023

Segment Reporting [Abstract]

Schedule of Net Sales and Segment Contribution for Each Reportable Segment

Net sales and segment contribution by each reportable segment for the three months ended June 30, 2023 were as follows (in thousands):

	Wound & Surgical		Regenerative Medicine		Corporate & Other		Consolidated
Net sales	$	80,461	—		$	796	$	81,257
Cost of sales	12,736		—		847		13,583
Selling, general and administrative expense	38,500		—		13,425		51,925
Research and development expense	1,632		6,865		—		8,497
Restructuring	—		3,256		—		3,256
Amortization of intangible assets	—		—		191		191
Segment contribution	$	27,593	$	(10,121)
Investigation, restatement and related expense							1,017
Operating income							$	2,788
Supplemental information
Depreciation expense	$	395	$	72	$	220	$	687
Share-based compensation	$	1,845	$	(193)	$	2,408	$	4,060

Net sales and segment contribution by each reportable segment for the three months ended June 30, 2022 were as follows (in thousands):

	Wound & Surgical		Regenerative Medicine		Corporate & Other		Consolidated
Net sales	$	66,094	$	—	$	789	$	66,883
Cost of sales	10,838		—		985		11,823
Selling, general and administrative expense	38,681		—		17,112		55,793
Research and development expense	2,408		3,104		—		5,512
Amortization of intangible assets	—		—		173		173
Segment contribution	$	14,167	$	(3,104)
Investigation, restatement and related expense							3,218
Operating loss							$	(9,636)
Supplemental information
Depreciation expense	$	459	$	39	$	360	$	858
Share-based compensation	$	1,896	$	302	$	2,230	$	4,428

Net sales and segment contribution by each reportable segment for the six months ended June 30, 2023 were as follows (in thousands):

	Wound & Surgical		Regenerative Medicine		Corporate & Other		Consolidated
Net sales	$	151,090	—		$	1,843	$	152,933
Cost of sales	24,068		—		1,934		26,002
Selling, general and administrative expense	76,166		—		28,036		104,202
Research and development expense	3,154		11,839		—		14,993
Restructuring	—		3,256		—		3,256
Amortization of intangible assets	—		—		380		380
Segment contribution	$	47,702	$	(15,095)
Investigation, restatement and related expense							4,690
Operating loss							$	(590)
Supplemental information
Depreciation expense	$	784	$	135	$	482	$	1,401
Share-based compensation	$	3,228	$	259	$	4,918	$	8,405

Net sales and segment contribution by each reportable segment for the six months ended June 30, 2022 were as follows (in thousands):

	Wound & Surgical		Regenerative Medicine		Corporate & Other		Consolidated
Net sales	$	124,423	$	—	$	1,354	$	125,777
Cost of sales	19,967		—		1,792		21,759
Selling, general and administrative expense	72,725		—		32,638		105,363
Research and development expense	4,358		7,118		—		11,476
Amortization of intangible assets	—		—		345		345
Segment contribution	$	27,373	$	(7,118)
Investigation, restatement and related expense							5,770
Operating loss							$	(18,936)
Supplemental information
Depreciation expense	$	914	$	84	$	720	$	1,718
Share-based compensation	$	3,661	$	564	$	4,201	$	8,426